Amneal Risperidone Injection FDA Approval Schizophrenia - News Directory 3

Amneal Risperidone Injection FDA Approval Schizophrenia

September 5, 2025 Jennifer Chen Health
News Context
At a glance
  • Food and Drug governance (FDA) has approved an injectable extended-release suspension of risperidone (Amneal‌ Pharmaceuticals) for ‌the treatment of patients ⁢wiht schizophrenia.
Original source: pharmacytimes.com

Okay, I’m ready to craft a Google News-friendly article about the FDA approval of amneal Pharmaceuticals’ injectable extended-release risperidone for schizophrenia. I will follow your ⁢instructions meticulously, including the semantic branching, E-E-A-T signals, required components,⁤ adn final self-check.

“`html





FDA Approves injectable‌ Risperidone for <a href="https://www.newsdirectory3.com/breaking-the-silence-new-initiative-sparks-conversations-on-sex-education-in-iwate-exclusive-lecture-set-for-morioka-on-the-14th/" title="Breaking the Silence: New Initiative Sparks Conversations on Sex Education in Iwate, Exclusive Lecture Set for Morioka on the 14th">Schizophrenia</a>: What ‌It Means for patients


FDA Approves Injectable⁢ Risperidone ‍for Schizophrenia: A New Option for patients

The U.S. Food and Drug governance (FDA) has approved an injectable extended-release suspension of risperidone (Amneal‌ Pharmaceuticals) for ‌the treatment of patients ⁢wiht schizophrenia. This ⁤approval references Risperdal Consta (Janssen Biotech).The extended-release formulation will be⁤ available‍ in 12.5-,⁢ 25-, 37.5-,⁢ and 50-mg ⁢vials.1

Image credit: wladimir1804 | stock.adobe.com

What ⁤Happened? The ⁤FDA Approval Explained

The FDA’s approval of Amneal’s injectable risperidone⁣ marks a notable step ​forward in the treatment of ⁢schizophrenia.This long-acting injectable⁢ (LAI) formulation offers several potential advantages over daily